In Brief: IDEC Pharmaceuticals/Seikagaku
Executive Summary
IDEC Pharmaceuticals/Seikagaku: Enter PRIMATIZED antibody collaboration for development of CD23 antigen antibody for allergic rhinitis, asthma and other allergic conditions, IDEC announces Feb. 2. The Japanese glycoscience corporation "may provide up to $26 mil. in license fee payments and support for research and development at IDEC, dependent on reaching specific development milestones." The two companies will share product rights derived from the collaboration; IDEC will receive royalties on eventual product sales. IDEC says that antibodies against the CD23 receptor on certain white blood cells have been found to inhibit the production of immunoglobulin class E molecules, known to cause allergic conditions...